ISPE September 12, 2013 Gaining Efficiencies in Pharmaceutical Operations Pfizer’s Green Journey.
Goldman Sachs Healthcare Conference · · 2017-06-14This presentation includes forward- looking...
Transcript of Goldman Sachs Healthcare Conference · · 2017-06-14This presentation includes forward- looking...
Forward Looking Statements This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts, expected regulatory submissions and approvals and anticipated performance and potential of Pfizer's products and product candidates that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors that May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the US Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.
Strong Track Record of Product Approvals 22 Key Approvals (14 NME); 42 Pivotal Study Starts (2011 – YTD)
(As of May 2, 2017)
Phase 1 36
96 Total
214 Discovery Projects
Phase 2 17
Phase 3 32
Registration 11
Discovery Projects
Potential in 2017/18 for 15 Pivotal Studies & 10 Midsize Differentiated Approvals
(Adult / CAPiTA)
2018-2022 Focus: Delivering on Clinical Pipeline 2
W A V E
Vaccines: C. difficile, S. aureus & Pneumo Nextgen
Oncology: I-O Combos
Rare Disease: Gene Therapy
I&I: Next Generation JAK inhibitors
Internal Medicine: NASH, AD/PD
7 Property of Pfizer Inc. – For Internal Use Only
Vaccines 9. Clostridium Difficile
10. Staphylococcus Aureus
11. Pneumococcal Nextgen
Potential for up to 15 Blockbuster Approvals over next 5 Years Approximately half potentially receiving approval by 2020
NMEs & Combos Oncology
1. IO-IO: Doublet / Triplet
2. IO-Targeted / IO-Chemo
3. Targeted Cancer Agents
4. Ibrance Intermediate/High Risk eBC
5. Xtandi non meta. PROSPER/EMBARK
Inflammation & Immunology 6. JAK1 Atopic Dermatitis
7. JAK3, TYK2/JAK1 Alopecia
8. Xeljanz Psoriatic Arthritis & Ulcerative Colitis
Rare Disease & Internal Medicine 12. domagrozumab Duchenne
13. rivipansel Sickle Cell
14. tafamidis Cardiomyopathy
15. tanezumab Pain
Biosimilars Across Cancer & Inflammatory Diseases
Potential 2017/18 News Flow Xeljanz
PsA Action Date (US)
ertugliflozin T2D
Action Date (US)
Bosulif CML 1L
Action Date(US/EU)
Xeljanz UC
Action Date (US)
dacomitinib EGFR+ NSCLC
Submission(US/EU)
Sutent Adjuvant RCC
Action Date (US)
glasdegib + LDAC 1L AML Unfit
Submission(US/EU)
SPK-9001 Hemophilia B
Phase 1/2 Data
ACC, FK NASH
Phase 1 Data
Bavencio Doublets + 4-1BB,+OX-40 Phase 1/2 Data
p-Cadherin BiFx Cancer
Phase 1 Data
Bavencio Triplet + 4-1BB + OX-40
Phase 1 Data
2H 2017 1H 2018
LATE
STA
GE
EAR
LY S
TAG
E TFPI Hemophilia A&B
Phase 1 Data
Ibrance combo PDAC
Phase 1 Data
lorlatinib ALK+ NSCLC
Submission (US)
JAK1 Atopic Derm Phase 2 Data